Mursla Bio Joins Prestigious EVEREST Consortium toAdvance Extracellular Vesicle Research

Mursla Bio Joins Prestigious EVEREST Consortium toAdvance Extracellular Vesicle Research

Alarian.com - Mursla Bio, a leading company in Extracellular Vesicle (EV) science, announced today that it has been invited to join the EVEREST consortium, a consortium of 22 institutions across 11 European countries aiming to advance EV research and innovation for the benefit of patients. The selection demonstrates Mursla Bio's leadership in the field of EV-based disease surveillance and diagnostic tests.

The EVEREST project is a leading European initiative that brings together academic and industry partners to promote the exchange of expertise in EV science and its clinical applications. As an industry partner, Mursla Bio will provide oversight on the 'scaling and commercialization' work package for EV products, particularly for clinical diagnostics. Furthermore, Mursla Bio will host researchers from institutions across Europe and send staff members on secondments to other partners.

Mursla Bio's dynamic biopsy technology combines the accuracy and disease sub-typing capabilities of tissue biopsies with the ease of liquid biopsy sample collection, providing a non-invasive intervention with comprehensive biological insights. This is made possible by advanced EV science and an innovative extracellular omics approach, supported by Mursla Bio's technologies.

"We are pleased to have been selected into the EVEREST consortium as an industry partner," said Pierre Arsène, Founder and CEO of Mursla Bio. "Our cross-Atlantic expertise will guide the consortium in scaling up and commercializing clinically relevant products. Together, we aim to shape the best of EV research into highly innovative clinical tests that will benefit millions of patients over the next decade."

The EVEREST project begins in January 2025 and is coordinated by the University College Dublin. The project is funded by the European Union's Horizon Europe research and innovation program under grant agreement No 101183034.

Dr Tomás Dias, CSO of Mursla Bio, added that "initiatives like EVEREST which bring together academic and industry partners are essential to facilitate the translation of scientific discoveries into clinical insights. We are excited to be part of this consortium and contribute our expertise to channel the best of EV scientific innovations into clinical products."

With this appointment, Mursla Bio solidifies its position as a leader in EV science and commits to advancing the field through cutting-edge research, innovation, and collaboration with prominent institutions across Europe.